Treatment of chronic heart failure with carvedilol in daily practice: The SATELLITE survey experience

International Journal of Cardiology

Volumn 122, Issue 2, 2007, Pages 149-155

  Lainscak, Mitja ^a,b   Moullet, Christine ^c   Schön, Norbert ^d   Tendera, Michal ^e  

^a General Hospital Murska Sobota   (Slovenia)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d Kardiologische Praxis Mühldorf am Inn ^*  (Germany)

^e MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

blocker; Carvedilol; Chronic heart failure; Efficacy; Tolerability

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; BRADYCARDIA; CLINICAL PRACTICE; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HEALTH SURVEY; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; THORAX PAIN; TREATMENT RESPONSE; VISUAL ANALOG SCALE; WELLBEING;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; CARBAZOLES; CARDIAC OUTPUT, LOW; COMORBIDITY; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PROPANOLAMINES; PROSPECTIVE STUDIES;

EID: 35148854645     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.08.001     Document Type: Article

References (30)

1. Cleland J.G.F., and Clark A.L. Delivering the cumulative benefits of triple therapy to improve outcomes in heart failure: too many cooks will spoil the broth. J Am Coll Cardiol 42 (2003) 1234-1237
2. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005). Eur Heart J 26 (2005) 1115-1140
3. Shibata M.C., Flather M.D., and Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 3 (2001) 351-359
4. The CAPRICORN investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. Lancet 357 (2001) 1385-1390
5. Packer M., Bristow M.R., Cohn J.N., et al. The effects of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334 (1996) 1349-1355
6. Packer M., Coats A.J., Fowler M.B., et al. Carvedilol prospective randomized cumulative survival study group. Effects of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
7. Poole-Wilson P.A., Swedberg K., Cleland J.G.F., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003) 7-13
8. Remme W.J., Riegger G., Hildebrandt P., et al. The benefits of early combination treatment of carvedilol and an ACE inhibitor in mild heart failure and left ventricular systolic dysfunction. The Carvedilol and ACE-inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN). Cardiovasc Drugs Ther 18 (2004) 57-66
9. Komajda M., Lapuerta P., Hermans N., et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J 26 (2005) 1653-1659
10. Cleland J.G.F., Cohen-Solal A., Aguilar Cosin J., et al. Management of heart failure in primary care (the IMPROVEMENT of heart failure programme): an international survey. Lancet 360 (2002) 1631-1639
11. Komajda M., Follath F., Swedberg K., et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe; Part 2: treatment. Eur Heart J 24 (2003) 464-475
12. Lainscak M., Horvat A., and Keber I. The management of patients with heart failure in Slovenian community hospital: what has changed from 1997 to 2000?. Wien Klin Wochenschr 115 (2003) 334-339
13. Di Lenarda A., Scherillo M., Maggioni A.P., et al. Current presentation and management of heart failure in cardiology and internal medicine hospital units: a tale of two worlds - the TEMISTOCLE study. Am Heart J 146 (2003) e12
14. Lenzen M.J., Boersma E., Scholte op Reimer W.J.M., et al. Under-utilization of evidence-based treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Eur Heart J 26 (2005) 2706-2713
15. Maggioni A.P., Sinagra G., Opasich C., et al. Treatment of chronic heart failure with β adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. Heart 89 (2003) 299-305
16. Ko D.T., Hebert P.R., Coffey C.S., et al. Adverse effects of β-blocker therapy for patients with heart failure. Arch Intern Med 164 (2004) 1389-1394
17. Lainščak M., Cleland J.G.F., Lenzen M.J., Follath F., Komajda M., and Swedberg K. International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure survey. Eur J Heart Fail 9 (2007) 292-299
18. Houpe D., Peltier M., Cohen-Solal A., et al. Heart failure due to left ventricular systolic dysfunction: treatment at discharge from hospital and at one year. Int J Cardiol 103 (2005) 286-292
19. Jain A., Mills P., Nunn L.M., et al. Success of a multidisciplinary heart failure clinic for initiation and up-titration of key therapeutic agents. Eur J Heart Fail 7 (2005) 405-410
20. Lainscak M., and Keber I. Heart failure clinic in a community hospital improves outcome in heart failure patients. Swiss Med Wkly 136 (2006) 274-280
21. Krum H., Hill J., Fruhwald F., et al. Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA-II study. Eur J Heart Fail 8 (2006) 302-307
22. Franciosa J.A., Massie B.M., Lukas M.A., et al. β-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry. Am Heart J 148 (2004) 718-726
23. Komajda M., Anker S.D., Charlesworth A., et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 27 (2006) 1440-1446
24. Cleland J.G.F., Swedberg K., Follath F., et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe; Part 1: patient characteristics and diagnosis. Eur Heart J 24 (2003) 442-463
25. Opasich C., Boccanelli A., Cafiero M., et al. Programme to improve the use of beta-blockers for heart failure in the elderly and in those with severe symptoms: results of the BRING-UP 2 Study. Eur J Heart Fail 8 (2006) 649-657
26. Bristow M.R., Gilbert E.M., Abraham W.T., et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94 (1996) 2807-2816
27. Ansari M., Shlipak M.G., Heidenreich P.A., et al. Improving guideline adherence: a randomized trial evaluating strategies to increase beta-blocker use in heart failure. Circulation 107 (2003) 2799-2804
28. Andersson B., Kjörk E., and Brunlöf G. Temporal improvement in heart failure survival related to the use of a nurse-directed clinic and recommended pharmacological treatment. Int J Cardiol 104 (2005) 257-263
29. Jaarsma T., Strömberg A., de Geest S., et al. Heart failure management programmes in Europe. Eur J Cardiovasc Nurs 5 (2006) 197-205
30. Flather M.D., Shibata M.S., Coats A.J.S., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 (2005) 215-225